BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Oncodaily, Yahoo Finance, TradingView and GenomeWeb. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2d ago.
Quick answers
Why is "BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analyst" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (14)
- BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival BioSpace · 3d ago
- Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? The Globe and Mail · 3d ago
- Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement TradingKey · 3d ago
- BioNTech's mRNA cancer therapy misses first goal in head and neck trial Reuters · 3d ago
- Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC OncLive · 3d ago
- BioNTech's HPV-targeted cancer vaccine misses PFS goal FirstWord Pharma · 3d ago
- BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’ TradingView · 3d ago
- BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC Oncodaily · 3d ago
- BioNTech stock falls after cancer trial misses key endpoint Yahoo Finance · 3d ago
- BioNTech's mRNA cancer therapy misses first goal in head and neck trial TradingView · 3d ago
- BioNTech mRNA Trial Will Keep Tracking Overall Survival After Initial Progress-Free Survival Failure GenomeWeb · 3d ago
- BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer CancerNetwork · 3d ago
- BioNTech Says Cancer Treatment Didn’t Help in Early Analysis Bloomberg.com · 3d ago
- BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence Fierce Biotech · 3d ago
Topics
Related trends
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
What you need to know about this year’s fall vaccines
Health authorities and medical groups are updating guidance for the 2026 fall respiratory vaccine season, including new cost structures in Australia.
The updated COVID-19 vaccines have just been approved. Here’s what you can expect.
The US FDA has approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine as updated shots become available to the public.
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.